EP12.02-07 The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan

ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) rearrangement is a rare driver oncogene found in 1% of non-small cell lung cancer (NSCLC). Although crizotinib and entrectinib have been approved by the FDA and shown robust efficacy in first-line treatment of ROS1-rearranged NSCLC patients, the role of lorlatinib, a novel third-generation tyrosine kinase inhibitor targeting anaplastic lymphoma kinase and ROS1, in treating such patients remain unclear. We aimed to evaluate the real-world effectiveness and safety of lorlatinib for previously treated ROS1-rearranged NSCLC patients.